2025
Addressing Peri-Device Leaks in Next-Generation Transcatheter Left Atrial Appendage Occluders: An Open Question
Roshanfar M, Jang S, Sinusas A, Wong S, Mosadegh B. Addressing Peri-Device Leaks in Next-Generation Transcatheter Left Atrial Appendage Occluders: An Open Question. Surgeries 2025, 6: 15. DOI: 10.3390/surgeries6010015.Peer-Reviewed Original ResearchPeri-device leakLeft atrial appendageFDA-approved devicesRisk of thrombo-embolic eventsNon-valvular atrial fibrillationLeft atrial appendage anatomyLong-term anticoagulationPercutaneous LAA occlusionCHA2DS2-VASc scoreThrombo-embolic eventsIncreased risk of strokeRisk of strokeCircular cross-sectionLeft atrial appendage occluderSystemic embolismAnticoagulant therapyLAA occlusionObservational registryCHA2DS2-VAScNon-pharmacological alternativeAdverse eventsAtrial fibrillationAtrial appendageClinical dataIncreased risk
2022
Tricuspid and mitral remodelling in atrial fibrillation: a three-dimensional echocardiographic study
Ortiz-Leon XA, Posada-Martinez EL, Trejo-Paredes MC, Ivey-Miranda JB, Pereira J, Crandall I, DaSilva P, Bouman E, Brooks A, Gerardi C, Houle H, Hur DJ, Lin BA, McNamara RL, Lombo-Lievano B, Akar JG, Arias-Godinez JA, Sugeng L. Tricuspid and mitral remodelling in atrial fibrillation: a three-dimensional echocardiographic study. European Heart Journal - Cardiovascular Imaging 2022, 23: 944-955. PMID: 35243501, DOI: 10.1093/ehjci/jeac045.Peer-Reviewed Original ResearchConceptsAtrial fibrillationMitral annulusVentricular functionLV functionSinus rhythmThree-dimensional echocardiographic studyImpact of AFNon-valvular atrial fibrillationNormal left ventricular functionTricuspid annulus dilationLV systolic dysfunctionNormal LV functionLeft ventricular functionAbnormal ventricular functionMA dilationTA dilationSystolic dysfunctionFunctional regurgitationAtrial enlargementEchocardiographic studyTransoesophageal echocardiographyAF groupAnnulus dilationAtrioventricular valvePatients
2021
Change in hospitalization rates following transcatheter left atrial appendage occlusion
Mohammed M, Kattel S, Ahsan I, Samdani AJ, Chand S, Rai D, Bandyopadhyay D, Ranka S, Noheria A, Gupta SK, Sheldon SH, Rao M, Aronow WS, Freeman JV, Reddy M. Change in hospitalization rates following transcatheter left atrial appendage occlusion. Archives Of Medical Science - Atherosclerotic Diseases 2021, 6: e191-e195. PMID: 36161215, PMCID: PMC9487831, DOI: 10.5114/amsad.2021.111405.Peer-Reviewed Original ResearchAtrial appendage occlusionOral anticoagulantsAtrial fibrillationAppendage occlusionHospitalization ratesLong-term oral anticoagulantsNon-valvular atrial fibrillationDiagnosis of AFNationwide Readmissions DatabaseCause admissionsHospital stayIndex procedureMore admissionsHigh riskPatientsClinical practiceAverage preAdmissionMortality informationLAAOSignificant decreaseContraindicationsIncidenceMonthsOcclusionAssociation between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study
Wong A, Tomlinson L, Brown J, Elson W, Walker A, Schultze A, Morton C, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch C, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis H, Mehrkar A, Cockburn J, McDonald H, Mathur R, Wing K, Forbes H, Eggo R, Evans S, Smeeth L, Goldacre B, Douglas I. Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study. Journal Of Hematology & Oncology 2021, 14: 172. PMID: 34666811, PMCID: PMC8525065, DOI: 10.1186/s13045-021-01185-0.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPopulation-based cohort studyCOVID-19-related outcomesSevere COVID-19Oral anticoagulantsCohort studyHazard ratioLower riskNegative control outcome analysisSevere COVID-19 diseaseNon-valvular atrial fibrillationPrimary care dataCOVID-19 outcomesCOVID-19COVID-19 diseaseNegative control outcomesDOAC usersOpenSAFELY platformWarfarin usersHospital admissionAtrial fibrillationClinical evidenceCox regressionResultsA totalOutcome analysis
2018
Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials
Romero J, Cerrud-Rodriguez R, Diaz J, Michaud G, Taveras J, Alviz I, Grupposo V, Cerna L, Avendano R, Kumar S, Kirchhof P, Natale A, Di Biase L. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. EP Europace 2018, 20: 1612-1620. PMID: 29982383, DOI: 10.1093/europace/euy133.Peer-Reviewed Original ResearchConceptsNon-valvular atrial fibrillationUninterrupted direct oral anticoagulantsUninterrupted vitamin K antagonistsDirect oral anticoagulantsVitamin K antagonistsMajor bleeding eventsSilent cerebral infarctionThrombo-embolic eventsCatheter ablationBleeding eventsAtrial fibrillationMajor bleedingK antagonistsOral anticoagulantsSystematic reviewBrain magnetic resonance imagingMinor bleeding eventsFirst-line therapyParoxysmal atrial fibrillationRandom-effects modelMagnetic resonance imagingFixed-effects modelMinor bleedingCerebral infarctionLine therapy
2017
Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya
Temu TM, Lane KA, Shen C, Ng'ang'a L, Akwanalo CO, Chen PS, Emonyi W, Heckbert SR, Koech MM, Manji I, Vatta M, Velazquez EJ, Wessel J, Kimaiyo S, Inui TS, Bloomfield GS. Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya. PLOS ONE 2017, 12: e0185204. PMID: 28934312, PMCID: PMC5608343, DOI: 10.1371/journal.pone.0185204.Peer-Reviewed Original ResearchConceptsValvular AFValvular heart diseaseAtrial fibrillationNVAF patientsAF patientsHeart diseaseNon-valvular atrial fibrillationGlobal cardiovascular disease burdenValvular atrial fibrillationRates of hypertensionCardiovascular disease burdenLong-term outcomesProspective data collectionAnticoagulation therapyClinical characteristicsCohort studyClinical profileHeart failureOverall mortalityClinical featuresComorbid conditionsFatal outcomeMean ageFemale sexDisease burdenNovel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
Mezue K, Obiagwu C, John J, Sharma A, Yang F, Shani J. Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban. Current Cardiology Reviews 2017, 13: 41-46. PMID: 27450450, PMCID: PMC5324317, DOI: 10.2174/1573403x12666160720092024.Peer-Reviewed Original ResearchConceptsFood and Drug AdministrationAtrial fibrillationReversal agentsClinical trialsNon-valvular atrial fibrillationSignificant mitral stenosisNovel oral anticoagulantsUS Food and Drug AdministrationOnset of actionPrimary safety outcomeClinical trial dataPrevention of strokeRate of strokeInhibitors of factor XaProsthetic heart valvesClinical bleedingApixaban useSystemic embolismOral anticoagulantsINR monitoringMitral stenosisDose variabilityNOACsApixabanCardiac arrhythmias
2012
Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation
Jang S, Kim M, Park H, Han S, Kang D, Song J, Park S, Park S, Kim J. Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart 2012, 99: 17. PMID: 22942291, DOI: 10.1136/heartjnl-2012-301980.Peer-Reviewed Original ResearchConceptsIschemic strokeNormal ejection fractionRisk of strokeAtrial fibrillationHeart failureEjection fractionNon-valvular atrial fibrillationChronic kidney diseaseDiabetes mellitusKidney diseaseFemale sexMyocardial infarctionEchocardiographic dataHFNEFTreatment weightingPropensity score methodsΒ-blockersPatientsStrokeInverse probabilityDeathFibrillationRiskScore methodFailure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply